S3V Vascular Technologies Unlisted Share Price Today
ISIN INE0HGT01012.
About Company S3V Vascular Technologies is a specialized medical device manufacturer based in Mysuru, India, focused on developing indigenous solutions for cardiovascular and neurovascular interventions. Originally established as a cardiac stent manufacturer (Drug-Eluting Stents and PTCA Balloons), the company is currently pivoting to become India's first integrated player in the Neurovascular segment. It is developing affordable mechanical thrombectomy kits for stroke treatment to replace ex…
S3V Vascular Technologies
S3V Vascular Technologies Unlisted Share Price Today
About Company
S3V Vascular Technologies is a specialized medical device manufacturer based in Mysuru, India, focused on developing indigenous solutions for cardiovascular and neurovascular interventions. Originally established as a cardiac stent manufacturer (Drug-Eluting Stents and PTCA Balloons), the company is currently pivoting to become India's first integrated player in the Neurovascular segment. It is developing affordable mechanical thrombectomy kits for stroke treatment to replace expensive imports. The company recently converted to a Public Limited entity and is backed by prominent investors including the family offices of AM Naik and Madhusudan Kela.
Industry Overview
Disease burden and demand driver - Cardiovascular diseases are the leading cause of death globally (about 32% of global deaths in 2022). In India, multiple datasets and reports indicate CVD is a major share of total mortality, with some recent summaries citing “nearly 1 in 3” deaths.
Large cath-lab and PCI procedure ecosystem - India performs a high volume of coronary interventions; National Interventional Council (CSI) data for 2018 reported 4,38,351 PCIs across 709 centers, using 5,78,164 coronary stents.
Pricing structure is heavily policy-shaped in India - Coronary stents have been under price control, which directly impacts manufacturer margins, distributor economics, and hospital billing practices. A Government (PIB) note on NPPA’s 2017 ceiling prices cites ₹29,600 for DES and ₹7,260 for BMS, and also highlights hospital billing and compliance enforcement. (Ceiling prices have seen periodic revisions linked to WPI changes, which can move allowed MRPs modestly year to year.)
Revenue from operations fell from ₹18.9 Cr in FY23 to ₹13.6 Cr in FY25, reflecting a contraction in business activity.
Despite lower revenue, the company maintained an EBITDA margin of around 20%, indicating resilient operating efficiency.
After reporting a net loss of ₹3.2 Cr in FY24, the company returned to profitability with a PAT of ₹0.06 Cr in FY25, while EPS also turned positive.
